# Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

> **NCT04544267** · PHASE3 · TERMINATED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 100 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Quadrivalent influenza vaccine, high-dose
- **BIOLOGICAL:** Quadrivalent influenza vaccine, standard dose

## Key facts

- **NCT ID:** NCT04544267
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-15
- **Primary completion:** 2021-06-02
- **Final completion:** 2021-06-02
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** The study was interrupted due to COVID-19 pandemic and terminated due to new changes to the recommendations for flu vaccines
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544267, "Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04544267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*